Oncopeptides AB (publ) (STO:ONCO)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.635
-0.185 (-10.16%)
May 22, 2026, 5:29 PM CET

Oncopeptides AB Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-221.1-249.59-284.61-249.11-337.95-1,430
Depreciation & Amortization
9.679.679.7511.0416.8414.57
Other Amortization
----0.320.42
Asset Writedown & Restructuring Costs
-----16.59
Stock-Based Compensation
2.722.7210.9111.514.8114.54
Other Operating Activities
23.9820.136.064.14-3.84-94.11
Change in Accounts Receivable
8.548.54-4.3-16.0253.1724.66
Change in Inventory
-3.87-3.87-1.95-2.42-1.46-0.32
Change in Accounts Payable
-17.47-17.473.15-13.19-22.89-104.91
Change in Other Net Operating Assets
-2.626.990.42-25.42-139.5242.49
Operating Cash Flow
-200.16-222.88-260.57-279.49-420.51-1,516
Capital Expenditures
---0.36-0.12-2.51-0.34
Investment in Securities
--0.85-0--
Other Investing Activities
--00--
Investing Cash Flow
--0.5-0.12-2.51-0.34
Long-Term Debt Repaid
--8.16-8.03-9.14-15.54-15.41
Net Debt Issued (Repaid)
-8.16-8.16-8.03-9.14-15.54-15.41
Issuance of Common Stock
151.41151.41313.48116.02436.021,116
Other Financing Activities
157.51-14.7-41.64--28.07-67.05
Financing Cash Flow
300.76128.55263.81106.89392.41,034
Foreign Exchange Rate Adjustments
-2.67-1.951.391.6112.944.63
Miscellaneous Cash Flow Adjustments
----0--0
Net Cash Flow
97.93-96.285.13-171.11-17.67-478.07
Free Cash Flow
-200.16-222.88-260.93-279.61-423.02-1,517
Free Cash Flow Margin
-240.47%-313.40%-824.47%-793.89%-5063.03%-1282.16%
Free Cash Flow Per Share
--0.98-1.57-3.09-5.14-20.14
Cash Interest Paid
2.82.800.570.880.95
Cash Income Tax Paid
0.110.11-0.59-1.650.0412.22
Levered Free Cash Flow
-120.6-138.49-169.03-191.36-289.31-1,086
Unlevered Free Cash Flow
-111.57-129.46-161.12-187.74-288.76-1,086
Change in Working Capital
-15.42-5.82-2.68-57.06-110.69-38.08
Source: S&P Global Market Intelligence. Standard template. Financial Sources.